Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | AGPAT2 | O15120 | 7/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 3/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757233 | 0.92 | MAPT (0.48) | PTPN1AGPAT2KDM4EMAPTTDP1 | |
| SCHEMBL3762341 | 0.91 | AGPAT2 (0.42) | AGPAT2KDM4EMAPTTDP1DHFR | |
| SCHEMBL3761275 | 0.87 | AGPAT2 (0.40) | AGPAT2KDM4EHSP90AA1HSP90AB1MPO | |
| SCHEMBL3760969 | 0.86 | L3MBTL1 (0.47) | PTPN1AGPAT2HSP90AA1HSP90AB1MPO | |
| SCHEMBL3761388 | 0.83 | NOS1 (0.50) | NOS1 | |
| SCHEMBL3760895 | 0.83 | MPO (0.40) | PTPN1KDM4EMAPTTDP1HSP90AA1 | |
| SCHEMBL11911418 | 0.82 | KDM4E (0.46) | PTPN1AGPAT2HTR2BPDE4DKDM4E | |
| SCHEMBL4450439 | 0.82 | NOS1 (0.46) | DHFRNOS1 | |
| SCHEMBL3760491 | 0.81 | PIK3CG (0.49) | DHFRMPONOS1 | |
| SCHEMBL3755307 | 0.81 | PTPN1 (0.44) | PTPN1MPONOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-12-02 | — | — | US | claimed |
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-05-23 | — | — | US | disclosed |
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | GILEAD SCIENCES, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2008009079-A2 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HCCS, DPYD, HAVCR2 | PTPN1 2905/4885AGPAT2 3435/4885HTR2B 3082/4885 |
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | HCCS, DPYD, HAVCR2 | PTPN1 2905/4885AGPAT2 3435/4885HTR2B 3082/4885 |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HCCS, DPYD, HAVCR2 | PTPN1 2905/4885AGPAT2 3435/4885HTR2B 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.